PCI to acquire Penn Pharma
- Penn Pharma is headquartered in Wales in the UK and also has offices in New Hope, PA and Tokyo, Japan.
- Penn Pharma recently opened a manufacturing facility specializing in creating containers for solid, oral-dose products.
- PCI specializes in clinical trial and commercial supply services.
According to Bill Mitchell, President and CEO of PCI, acquiring Penn Pharma will allow PCI to partner with clients at the earliest stages of drug development. The synergy between Penn and PCI will allow PCI to support formulation, analytical development, manufacturing, packaging, distribution and the eventual launch of various products, Mitchell said. PCI, which has recently made several other investments, has facilities in Philadelphia; Rockford, IL; Woodstock, IL and Hay-a-Wye UK.
- Pharmaceutical Business Review PCI announces definitive agreement to acquire Penn Pharma